Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Cost-effectiveness
100%
MR Angiography
100%
Renovascular Hypertension
100%
Conventional Angiography
100%
Patient-centered Outcomes
100%
Imaging Strategy
100%
Medical Therapy
83%
Resistant Hypertension
66%
Renal Artery Stenosis
50%
Disutility
50%
Natural History
33%
Myocardial Infarction
33%
End-stage Renal Disease
33%
Imaging Tests
33%
Hypertension
33%
Quality of Life
33%
CT Angiography
33%
Direct Costs
33%
Dialysis
16%
Blood Pressure
16%
Blood Pressure Response
16%
Diagnostic Test
16%
Life Expectancy
16%
Effective Alternative
16%
Patient-centered
16%
Quality of Life Assessment
16%
Cost-effectiveness Analysis
16%
Stent Treatment
16%
Patients with Hypertension
16%
Cost-effective Strategy
16%
Decision-analytic Model
16%
Incremental Cost-effectiveness Ratio
16%
Renal Artery Stenting
16%
Medicare Reimbursement
16%
Incremental Cost
16%
Life Adjustment
16%
Competitive Strategy
16%
Nursing and Health Professions
Imaging
100%
Cost Effectiveness Analysis
100%
Renovascular Hypertension
100%
Magnetic Resonance Angiography
85%
Conventional Angiography
85%
Combination Therapy
71%
Resistant Hypertension
57%
Kidney Artery Stenosis
42%
Base
28%
End Stage Renal Disease
28%
Heart Infarction
28%
Stent
28%
Cerebrovascular Accident
28%
Blood Pressure
28%
Computed Tomographic Angiography
28%
Quality of Life
28%
Reimbursement
14%
Medicare
14%
Diagnostic Test
14%
Life Expectancy
14%
Quality of Life Measure
14%
Incremental Cost-Effectiveness Ratio
14%
Patient with Hypertension
14%
Medicine and Dentistry
Health Care Cost
100%
Cost-Effectiveness Analysis
100%
Renovascular Hypertension
100%
Magnetic Resonance Angiography
54%
Conventional Angiography
54%
Combination Therapy
45%
Resistant Hypertension
36%
Renal Artery Stenosis
27%
Myocardial Infarction
18%
Base
18%
End Stage Renal Disease
18%
Blood Pressure
18%
Apoplexy
18%
Quality of Life
18%
Computed Tomography Angiography
18%
Stenting
9%
Medicare
9%
Renal Artery
9%
Diagnostic Test
9%
Life Expectancy
9%
Patient with Hypertension
9%
Quality of Life Measure
9%
Pharmacology, Toxicology and Pharmaceutical Science
Combination Therapy
100%
Renovascular Hypertension
100%
Resistant Hypertension
80%
Kidney Artery Stenosis
60%
Heart Infarction
40%
Base
40%
End Stage Renal Disease
40%
Cerebrovascular Accident
40%
Life Expectancy
20%